Journals / Marmara Medical Journal / 2013 / Cilt: 26 - Sayı: 1

-

Hafif-orta şiddetli akne vulgaris yüz tutulumu tedavisinde nadifloksasinin tek başına ve benzoil peroksit ile birlikte kullanımının karşılaştırılması

Pages
17–20
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Both treatment regimens were well tolerated with mild side effects

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To compare the efficacy of nadifloxacin alone and with benzoyl peroxide in the treatment of mild to moderate facial acne vulgaris.
📊
Key Findings & Data:Patients and Methods: This double-blind, randomized study was conducted in a total of 93 acne patients, with at least 10 inflammatory lesions, but no more than 3 nodules or cysts on the face.
💡
Conclusion & Impact:Both treatment regimens were well tolerated with mild side effects
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Akne · Nadifloksasin · Benzoil peroksit

Abstract

Objective: To compare the efficacy of nadifloxacin alone and with benzoyl peroxide in the treatment of mild to moderate facial acne vulgaris. Patients and Methods: This double-blind, randomized study was conducted in a total of 93 acne patients, with at least 10 inflammatory lesions, but no more than 3 nodules or cysts on the face. All patients were instructed to apply nadifloxacin 1% cream twice daily and randomized to apply either benzoyl peroxide 5% lotion or its vehicle once daily for 8 weeks. Results: The mean percent reduction in inflammatory lesions were 22.08% in the nadifloxacin group (n=46) and 53.5% in the nadifloxacin+benzoyl peroxide group (n=47). Five (10.9%) patients in the nadifloxacin group and 18 (38.3%) patients in the nadifloxacin+benzoyl peroxide group achieved a 50% and greater reduction in the inflammatory lesion count. Conclusion: Both treatment regimens were statistically effective, but a significantly greater reduction of the inflammatory lesions was seen in the nadifloxacin+benzoyl peroxide group. The number of patients who achieved a 50% and greater reduction in inflammatory lesion count was significantly higher in the nadifloxacin+benzoyl peroxide group. Both treatment regimens were well tolerated with mild side effects

Özet

Amaç: Hafif-orta şiddetli akne vulgaris tedavisinde nadifloksasin kremin tek başına veya benzoil peroksit ile birlikte kullanımının etkinliğini karşılaştırma. Hastalar ve Yöntem: Çift kör, randomize çalışma, toplam 93 hasta 2 grup olarak ya nadifloksasin kremi ya benzoil peroksit losyonun baz formu ya da benzoil peroksit ile birlikte 8 hafta süre ile kullandı. Bulgular: İnflamatuar lezyonlar tek başına nadifloksasin kullanan grupta(n=46) %22, 08, nadifloksasin+benzoil peroksit kullanan grupta(n=47) %53,5 oranında azaldı. Tek başına nadifloksasin kullanan grupta beş (%10,9), nadifloksasin+benzoil peroksit kullanan grupta 18(%38,3)hastada inflamatuar lezyonlarda %50 ve üzeri azalma görüldü. Sonuç: Her iki tedavi de istatistiksel olarak etkili bulundu ancak nadifloksasin+benzoil peroksit grubunda belirgin olarak inflamatuar lezyonlarda azalma görüldü. Her iki tedavi de hafif yan etkiler ile çok iyi tolere edildi

🔖

Cite This Article

ÖZGEN, Z. Y., GÜRBÜZ, O. (2013). -. Marmara Medical Journal, Cilt: 26 - Sayı: 1, 17–20. https://ajindex.com/articles/284407

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Thiboutat D, Gollnick H, Bettoli V, et al. New insights into the managements of acne: an update from the Global Alliance to improve outcomes in acne group. J Am Acad Dermatol 2009
  2. 60 (5 Suppl): S1- 50. doi: 10.1016/j.jaad.2009.01.019 2. Gollnick H, Cunliffe W, Berson D, et al. Global alliance to improve outcomes in acne. J Am Acad Dermatol 2003
  3. 49 (1 Suppl): S1-37. 3. Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia. Br J Dermatol 2001
  4. doi:10.1046/j.1365-2133.2001.03956.x 4. Leyden J, Levy S. The development of antibiotic resistance in Propionibacterium acnes in acne. Cutis 2001
  5. 67 (2 suppl): 21-4. 5. Coates P, Vyakrnam S, Eady EA, et al. Prevelance of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distrubution study. Br J Dermatol 2002
  6. doi:10.1046/j.1365-2133.2002.04690.x 6. Kawabata S, Ohguro K, Mukai F, et al. Bacteriological evaluation of OPC-7251, a new pyridone carboxylic acid antimicrobial agent. 1: In vitro antibacterial activity. Chemotherapy 1989
  7. Kurukawa I, Akamatsu H, Nishijima S, et al. Clinical and bacteriologic evalution of OPC-7251 in patients with acne: a double-blind group comparison study versus cream base. J am Acad Dermatol 1991
  8. Jung JY, Kwan HH, Yeau KB, et al. Clinical and histological evalution of 1% nadifloxacin cream in the treatment of acne vulgaris in Korean patients. Int J Dermatol 2011
  9. doi:10.1111/j.1365- 4632.2010.04701.x 9. Plewig G, Holland KT, Nenoff P. Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris: a doubleblind, phase 3 comparison study versus erythromycin 2% cream. Eur J Dermatol 2006
  10. doi:10.1586/17469872.1.5.643 10. Tunca M, Akar A, Ozmen I, et al. Topical nadifloxacin 1% cream vs. topical erythromycin 4% jel in the treatment of mild to moderate acne. Int J Dermatol 2010
  11. doi:10.1111/j.1365- 4632.2010.04601.x 11. Bojar RA, Hittel N, Cunliffe WJ, et al. Direct analysis of resistance in the cutaneous microflora during treatment of acne vulgaris with topical 1% nadifloxacin and 2% erythromycin. Drugs 1995
  12. 49 (Suppl 2): 164- 7. 12. Alba V, Urban E, Dominguez A, et al. In vitro activity of nadifloxacin against several Gram-positive bacteri